Last updated: 17 July 2019 at 9:43am EST

Ventures Vii, Llc Vivo Vent... Net Worth




The estimated Net Worth of Ventures Vii, Llc Vivo Vent... is at least $45.8 million dollars as of 28 February 2017. Ventures Vent owns over 425,000 units of MEI Pharma Inc stock worth over $184,135 and over the last 12 years Ventures sold MEIP stock worth over $45,612,907.

Ventures Vent MEIP stock SEC Form 4 insiders trading

Ventures has made over 12 trades of the MEI Pharma Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Ventures sold 425,000 units of MEIP stock worth $13,098,500 on 28 February 2017.

The largest trade Ventures's ever made was selling 907,828 units of MEI Pharma Inc stock on 16 November 2016 worth over $20,907,279. On average, Ventures trades about 268,459 units every 115 days since 2013. As of 28 February 2017 Ventures still owns at least 60,972 units of MEI Pharma Inc stock.

You can see the complete history of Ventures Vent stock trades at the bottom of the page.



Insiders trading at MEI Pharma Inc

Over the last 12 years, insiders at MEI Pharma Inc have traded over $26,282,680 worth of MEI Pharma Inc stock and bought 597,450 units worth $2,541,200 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Leaf Ventures Ii, L.P.New L... et Josiah T Austin. On average, MEI Pharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $360,383. The most recent stock trade was executed by Funds Management Lp Anson A... on 22 September 2023, trading 48,060 units of MEIP stock currently worth $329,211.



What does MEI Pharma Inc do?

mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.



Complete history of Ventures Vent stock trades at Aclaris Therapeutics Inc, Codexis et MEI Pharma Inc

Initié
Trans.
Transaction
Prix ​​total
Ventures Vii, Llc Vivo Vent...
Vente $13,098,500
28 Feb 2017
Ventures Vii, Llc Vivo Vent...
Vente $20,907,279
16 Nov 2016
Ventures Vii, Llc Vivo Vent...
Acheter $4,999,995
13 Oct 2015
Ventures Vii, Llc Vivo Vent...
Acheter $146,872
7 Oct 2015
Ventures Vii, Llc Vivo Vent...
Vente $474,300
8 Sep 2016
Ventures Vii, Llc Vivo Vent...
Vente $369,300
15 Aug 2016
Ventures Vii, Llc Vivo Vent...
Vente $337,600
3 Aug 2016
Ventures Vii, Llc Vivo Vent...
Vente $2,459,790
25 Oct 2013
Ventures Vii, Llc Vivo Vent...
Vente $5,909,523
1 Oct 2013
Ventures Vii, Llc Vivo Vent...
Vente $55,614
28 Jun 2013
Ventures Vii, Llc Vivo Vent...
Vente $1,842,929
11 Jun 2013
Ventures Vii, Llc Vivo Vent...
Vente $158,072
16 May 2013


MEI Pharma Inc executives and stock owners

MEI Pharma Inc executives and other stock owners filed with the SEC include: